Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …

Background Patients with type 2 diabetes (T2D) have a substantial increased risk for
cardiovascular (CV) disease and associated mortality than those without diabetes …

Background The REWIND trial demonstrated cardiovascular (CV) benefits to patients with
type 2 diabetes and multiple CV risk factors or established CV disease. This exploratory …

Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …

Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1
(GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on …

Aims To evaluate the efficacy and safety of dulaglutide 1.5 and 0.75 mg in patients with type
2 diabetes by subgroups of gender, duration of diabetes and baseline glycated …

Background Treating hyperglycaemia and obesity in individuals with type 2 diabetes using
multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a …

Diabet. Med. 29, 1260–1267 (2012) Abstract Aims Evaluate dose‐dependent effects of once‐
weekly dulaglutide, a glucagon‐like peptide‐1 analogue, on glycaemic control in patients …

OBJECTIVE Compare the efficacy and safety of monotherapy with dulaglutide, a once-
weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes. The …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-
glucose co-transporter-2 (SGLT2) inhibitors improve glycaemic control and reduce …